Drug · DIN 02565676
RETEVMO
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since August 4, 2026; first marketed August 4, 2026.
- Drug Identification Number (DIN)
- 02565676
- Company (DIN owner)
- Eli Lilly Canada IncToronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Selpercatinib L01EX22
- Class
- Human
- Record last updated
- August 14, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| SELPERCATINIB | 80 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 6, 2026: NOC 36852Supplement to a New Drug Submission (SNDS) · Product Monograph reformatted to the Master Template. Addition of new dosage form: Tablet.
Other DINs named RETEVMO
- DIN 02516918 · Marketed
- DIN 02516926 · Marketed
- DIN 02565668 · Approved